The PTAB, pharmaceutical patents and reverse payments
The authors of a new white paper believe that almost 75% of pharmaceutical patent settlements at the Patent Trial and Appeal Board meet the criterion for inferring a strong likelihood of reverse payment settlement. The paper also suggests a rule to deter attempts to exploit the Board as a holdup device as well as discussing reverse patent trolls
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: